MIAMI--(BUSINESS WIRE)--Cardone Ventures, backed by billionaire investor, Grant Cardone and his business partners Brandon and Natalie Dawson, today announced that it has submitted an unsolicited, non- binding proposal to acquire PetMed Express, Inc. (Nasdaq: PETS) ("PetMeds†) for $4.25 per share in cash, representing an implied equity value of approximately $89 million. The proposal was delivered to the Board of Directors of PetMed Express and is not subject to any financing contingency, reflect. ...

Core Viewpoint - PetMed Express, Inc. has received an unsolicited acquisition proposal from SilverCape Investments Limited to acquire all outstanding shares for $4 per share in cash, which is subject to due diligence and a definitive agreement but not contingent on financing [1][2] Company Overview - PetMed Express, Inc. is a pioneer in the direct-to-consumer pet healthcare sector, founded in 1996, and operates as a national online pharmacy licensed across all 50 states [3] - The company offers a comprehensive range of pet health solutions, including pharmaceuticals, compounded medications, and OTC supplements through its brands and PetCareRx subsidiary [3] - PetMed Express focuses on value, convenience, and care to empower pet parents in supporting the health of their pets [3]

DELRAY BEACH, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc., d/b/a PetMeds and parent company of PetCareRx, (Nasdaq: PETS) (the “Company”), today unveiled its new Holiday Collection, a curated selection of health, wellness, and lifestyle products designed for pet parents who want to give purposeful, practical gifts this season. Unlike traditional pet gifts such as toys or beds, PetMeds’ giftable assortment focuses on products that improve pets’ everyday health, comfort, safety, and happiness, ...

Company Overview - PetMed Express, Inc. is an online pet pharmacy founded in 1996, offering a wide range of medications, supplements, food, and other pet health products [3] Allegations and Stock Performance - On June 10, 2025, PetMed announced a delay in releasing its fourth-quarter and full-year 2025 financial results, leading to a stock drop of $0.47, or 11.22%, closing at $3.72 on June 11, 2025 [4] - On July 1, 2025, PetMed stated it would not file its fiscal-year 2025 Annual Report on time due to an internal review of revenue recognition, resulting in a stock decline of $0.05 per share, or 1.51%, finishing at $3.27 [5] - On November 12, 2025, PetMed reported it could not timely submit its third-quarter 2025 Form 10-Q due to an Audit Committee investigation, causing a significant stock price drop of $0.94 per share, or 32.41%, closing at $1.96 on November 13, 2025 [6] Legal Investigation - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving PetMed Express, stemming from allegations of providing misleading business information to the investing public [1]

Core Viewpoint - PetMed Express, Inc. has extended its shareholder rights plan for one year, reflecting the Board's belief that the company's shares do not currently represent its inherent value or long-term growth potential [1][2]. Summary by Sections Shareholder Rights Plan - The Board of Directors has unanimously approved an amendment to extend the expiration date of the Rights Plan from December 2, 2025, to December 2, 2026, with all other terms remaining unchanged [1][4]. - The Rights Plan aims to protect shareholders during a time of significant stock accumulation by certain shareholders, ensuring fair treatment and preventing control acquisition without appropriate compensation [2][3]. Company Background - PetMed Express, Inc. is a pioneer in the direct-to-consumer pet healthcare sector, offering a wide range of pet health solutions through its brands, including PetCareRx [5]. - The company is licensed across all 50 states and focuses on providing value, convenience, and care to pet owners [5].

Core Viewpoint - Pets at Home experienced a share price increase despite reporting weak trading results, as the company avoided another profit warning [2] Financial Performance - Revenues for the 28 weeks ending on 9 October decreased by 1.3% to £778.3 million, while pre-tax profit fell by 29.1% to £36.2 million [2] - The retail division saw a year-on-year sales decline of 2.3%, totaling £679.9 million, with underlying pre-tax profit plummeting by 84.1% to £3.5 million [5] - Underlying pre-tax profit margins in the retail segment dropped by 260 basis points to 0.5% due to discounting, adverse product mix, and lower supplier income [5] - The veterinary services unit reported a revenue increase of 6.7% to £375.9 million, with underlying pre-tax profit rising by 8.3% to £44.9 million and margins improving by 90 basis points to 45.7% [6] Management and Strategy - The interim CEO Ian Burke emphasized the need for urgent action to return the retail business to growth and stabilize operations [7] - The company is in search of a new CEO following the departure of Lyssa McGowan, who left after the second profit warning of 2025 [7] Market Insights - Analyst Mark Crouch highlighted the disparity between the struggling retail arm and the resilient veterinary division, indicating that the retail sector requires immediate revival [8] - Concerns were raised about the increasing debt levels on the balance sheet and the potential for a structural slump in consumer demand [8]

Core Viewpoint - PetMed Express, Inc. has announced preliminary second quarter fiscal year 2026 results, indicating a significant decline in net sales compared to the previous year, and has filed a Notification of Late Filing with the SEC due to delays in filing its Form 10-Q [1][2]. Financial Performance - For the fiscal second quarter ended September 30, 2025, net sales are estimated to range from $43.4 million to $44.5 million, a decrease from $58.0 million in the prior year period [2]. - For the six months ended September 30, 2025, net sales are estimated to range from $94.5 million to $95.6 million, down from $124.3 million in the prior year period [2]. - The company reported $36.1 million in cash and no debt as of September 30, 2025 [4]. Compliance and Regulatory Issues - On November 12, 2025, the company received a notice from Nasdaq indicating non-compliance due to delays in filing its Quarterly Reports for the periods ended June 30, 2025, and September 30, 2025 [5]. - The company must submit an update to its original plan to regain compliance by November 28, 2025, following a previous submission on September 2, 2025 [6]. - The notice does not have an immediate effect on the listing of the company's common stock on Nasdaq [6]. Operational Challenges - The company is currently unable to provide estimates for operating income or net income for the three- and six-month periods ended September 30, 2025, due to ongoing analysis of a potential goodwill impairment charge [3]. - The company is working diligently to complete and file its Q1 10-Q and Q2 10-Q as soon as possible to regain compliance with Nasdaq listing standards [7]. Company Overview - PetMed Express, Inc. is a pioneer in the direct-to-consumer pet healthcare sector, offering a range of pet health solutions through its brands, including PetCareRx [8]. - The company is licensed across all 50 states and focuses on providing value, convenience, and care to pet owners [8].

Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against PetMed Express, Inc. for possible violations of federal securities laws and unlawful business practices [1][2] Investigation Details - The investigation is focused on whether PetMed has engaged in any unlawful activities that may have affected its stockholders [1][2] - Investors who have suffered losses and are long-term stockholders are encouraged to reach out for more information regarding their rights [3] Company Background - Bragar Eagel & Squire, P.C. is a law firm that represents individual and institutional investors in various types of litigation across the United States [4] - The firm has offices in New York and California and specializes in commercial and securities litigation [4] Recent Developments - On June 10, 2025, PetMed announced a delay in releasing its fourth quarter and fiscal year 2025 earnings due to the need for additional time to complete the year-end audit [6] - Following this announcement, PetMed's stock price dropped by $0.47, or 11.22%, closing at $3.72 per share on June 11, 2025 [6]

Core Viewpoint - PetMed Express, Inc. has appointed James LaCamp to its Board of Directors, effective immediately, and he will become Chair of the Audit Committee on October 30, 2025, enhancing the company's financial governance and oversight capabilities [2][3]. Board Composition and Changes - The appointment of James LaCamp is part of PetMed's ongoing board refreshment strategy, which aims to build a board of independent and highly qualified directors to support profitable revenue growth and shareholder value creation [3][4]. - Since fiscal Q4 2024, notable changes to the board include Leslie C. G. Campbell becoming Chair of the Board, and the appointments of Justin Mennen, Leah Solivan, and Peter Batushansky, resulting in a board of six directors, five of whom are independent [3][4]. James LaCamp's Background - James LaCamp brings nearly 20 years of experience in finance, accounting, and corporate strategy, having served as Chief Financial Officer at various technology companies and as an Audit Partner at Deloitte & Touche LLP [5][6][7]. - Currently, LaCamp is the Chief Financial Officer of Skydio, overseeing all financial operations, and has held leadership roles in other technology firms, contributing to financial strategy and operations [7][8]. Company Overview - PetMed Express, founded in 1996, is a pioneer in the direct-to-consumer pet healthcare sector, offering a range of pet health solutions through its online pharmacy, licensed across all 50 states [10]. - The company focuses on value, convenience, and care, empowering pet parents to support the health of their pets [10].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against PetMed Express, Inc. for possible violations of federal securities laws and unlawful business practices affecting stockholders [1][2]. Investigation Details - The investigation is focused on whether PetMed has engaged in unlawful activities that could impact its stockholders [2]. - Investors who have suffered losses and are long-term stockholders are encouraged to reach out for more information regarding their rights and potential claims [3]. Company Background - Bragar Eagel & Squire, P.C. is a law firm recognized nationally, representing both individual and institutional investors in various types of litigation across state and federal courts [4]. - The firm has offices in New York and California and specializes in commercial, securities, and derivative litigation [4]. Recent Company Events - On June 10, 2025, PetMed announced a delay in releasing its fourth quarter and fiscal year 2025 earnings due to the need for additional time to complete the year-end audit process [6]. - Following this announcement, PetMed's stock price dropped by $0.47 per share, or 11.22%, closing at $3.72 per share on June 11, 2025 [6].